RBC Capital Expresses Positive Outlook on Sarepta Therapeutics Future Performance
On November 22, 2023, Brian Abrahams, an analyst at RBC Capital, expressed his positive outlook on Sarepta Therapeutics (NASDAQ: SRPT). ...
Tag: SRPT
RBC Capital Reaffirms Outperform Rating and 148 Price Target for Sarepta Therapeutics
On November 22, 2023, Brian Abrahams, an analyst at RBC Capital, expressed his confidence in Sarepta Therapeutics (NASDAQ: SRPT) by ...
Analyst Ratings for Sarepta Therapeutics A Range of Perspectives
Analyst ratings for Sarepta Therapeutics (NASDAQ: SRPT) have shown a diverse range of opinions over the past three months. These ...
Wedbush Analyst Initiates Coverage on Sarepta Therapeutics with an Optimistic Outlook
On November 21, 2023, Wedbush analyst Andreas Argyrides stepped forward to provide his insights on Sarepta Therapeutics (NASDAQ: SRPT), initiating ...
Insider Transactions Understanding the Significance and Limitations
On November 6, 2023, Douglas S. Ingram, the President & CEO of Sarepta Therapeutics, made a significant investment in the ...
Insider Transaction and its Significance in Investment DecisionMaking
On November 6, 2023, Richard Barry, the Director at Sarepta Therapeutics, made a significant investment by purchasing 50,000 shares of ...
Analyst Ratings and Price Targets for Sarepta Therapeutics
As of November 3, 2023, Sarepta Therapeutics has garnered the following analyst ratings over the past three months: - Bullish: ...
Sarepta Therapeutics Shines in Q3 2023 with Impressive Earnings and Sales Growth
Sarepta Therapeutics, a pioneering company in the field of precision genetic medicine for rare diseases, has released its impressive Q3 ...
Sarepta Therapeutics Faces Setback in Gene Therapy Trial but Seeks Expanded Approval
On November 1, 2023, Sarepta Therapeutics experienced a significant drop in its stock value during premarket trading. This decline came ...
Sarepta Therapeutics Faces Setback in ELEVIDYS Gene Therapy Study for Duchenne Muscular Dystrophy
On November 1, 2023, Sarepta Therapeutics made a significant announcement regarding the EMBARK study, a pivotal global study exploring the ...